RT Journal Article
T1 An immunological approach to the biocompatibility of mesoporous SiO2-CaO nanospheres.
A1 Montes-Casado, María
A1 Sanvicente, Adrián
A1 Casarrubios Molina, Laura
A1 Feito Castellano, María José
A1 Rojo, J.M.
A1 Arcos Navarrete, Daniel
A1 Vallet Regí, María Dulce Nombre
A1 Portoles, Pilar
A1 Portolés Pérez, María Teresa
AB Mesoporous bioactive glass nanospheres (NanoMBGs) have high potential for clinicalapplications. However, the impact of  nanoparticles on the immune system needs to be addressed.In this study, the biocompatibility of SiO2-CaO NanoMBGs was evaluated on different mouse immune cells, including spleen cells subsets, bone marrow-derived dendritic cells (BMDCs), or cell lines likevSR.D10 Th2 CD4+ lymphocytes and DC2.4 dendritic cells. Flow cytometry and confocal microscopy show that the nanoparticles were rapidly and efficiently taken up in vitro by T and B lymphocytes or by specialized antigen-presenting cells (APCs) like dendritic cells (DCs). Nanoparticles were not cytotoxic and had no effect on cell viability or proliferation under T-cell (anti-CD3) or B cell (LPS) stimuli. Besides, NanoMBGs did not affect the balance of spleen cell subsets, or the production of intracellular or secreted pro- and anti-inflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-6, IL-10) by activated T, B, and dendritic cells (DC), as determined by flow cytometry and ELISA. T cell activation surface markers (CD25, CD69 and Induced Costimulator, ICOS) were not altered by NanoMBGs. Maturation of BMDCs or DC2.4 cells in vitro was not altered by NanoMBGs, as shown by expression of Major Histocompatibility Complex (MHC) and costimulatory molecules (CD40, CD80, CD86), or IL-6 secretion. The effect of wortmannin and chlorpromazine indicate a role for phosphoinositide 3-kinase (PI3K), actin and clathrin-dependent pathways in NanoMBG internalization. We thus demonstrate that these NanoMBGs are both non-toxic and non-inflammagenic for murine lymphoid cells and myeloid DCs despite their efficient intake by the cells.
PB MDPI
SN 1422-0067
YR 2020
FD 2020-11-05
LK https://hdl.handle.net/20.500.14352/6720
UL https://hdl.handle.net/20.500.14352/6720
LA eng
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)RESEARCHER ID L-6167-2014 (Daniel Arcos Navarrete)ORCID 0000-0002-5367-7272 (Daniel Arcos Navarrete)RESEARCHER ID U-1678-2017 (María Teresa Portolés Pérez)ORCID 0000-0002-9681-0184 (María Teresa Portolés Pérez)
NO Unión Europea. Horizonte 2020
NO Ministerio de Economía y Competitividad (MINECO)/FEDER
NO Comunidad de Madrid
NO Instituto de Salud Carlos III  (ISCIII)
DS Docta Complutense
RD 30 abr 2024